gyeongshingangjeehwan

10/28/2018 - "These findings suggest that GGEx18 may be effective for preventing and treating NAFLD associated with visceral obesity."
02/01/2015 - "This study investigates the effects of GGEx18 on visceral obesity and insulin resistance and determines the molecular mechanisms involved in this process. "
10/28/2018 - "These results indicate that GGEx18 attenuates visceral obesity and NAFLD, in part by altering the expression of genes involved in hepatic steatosis and fibroinflammation in HFD-induced obese mice. "
02/01/2015 - "After C57BL/6J mice were fed a high-fat diet supplemented with GGEx18 (125, 250, and 500 mg/kg) for 8 weeks and 3T3-L1 adipocytes were treated with GGEx18 (0.1, 1, and 10 μg/ml); variables and determinants of visceral obesity and insulin resistance were measured using in vivo and in vitro approaches. "
02/01/2015 - "These results suggest that GGEx18 may treat visceral obesity and visceral obesity-related insulin resistance by upregulating the visceral adipose expression of fatty acid oxidative genes."

10/28/2018 - "This study investigated the effects of GGEx18 on nonalcoholic fatty liver disease (NAFLD) in mice fed a high-fat diet (HFD) and the underlying cellular and molecular mechanisms involved. "
10/28/2018 - "These findings suggest that GGEx18 may be effective for preventing and treating NAFLD associated with visceral obesity."
10/28/2018 - "These results indicate that GGEx18 attenuates visceral obesity and NAFLD, in part by altering the expression of genes involved in hepatic steatosis and fibroinflammation in HFD-induced obese mice. "

02/01/2015 - "GGEx18 normalized hyperglycemia and hyperinsulinemia in obese mice. "
08/10/2019 - "GGEx18 inhibited hyperglycemia and hyperinsulinemia and improved glucose and insulin tolerance. "

02/01/2015 - "GGEx18 normalized hyperglycemia and hyperinsulinemia in obese mice. "
08/10/2019 - "GGEx18 inhibited hyperglycemia and hyperinsulinemia and improved glucose and insulin tolerance. "

02/01/2015 - "This study investigates the effects of GGEx18 on visceral obesity and insulin resistance and determines the molecular mechanisms involved in this process. "
02/01/2015 - "After C57BL/6J mice were fed a high-fat diet supplemented with GGEx18 (125, 250, and 500 mg/kg) for 8 weeks and 3T3-L1 adipocytes were treated with GGEx18 (0.1, 1, and 10 μg/ml); variables and determinants of visceral obesity and insulin resistance were measured using in vivo and in vitro approaches. "
08/10/2019 - "GGEx18 curtailed impaired glucose metabolism and pancreatic steatosis in our mouse model by regulating pancreatic genes that govern lipid metabolism and improving insulin sensitivity. "
02/01/2015 - "These results suggest that GGEx18 may treat visceral obesity and visceral obesity-related insulin resistance by upregulating the visceral adipose expression of fatty acid oxidative genes."
02/01/2015 - "The herbal composition GGEx18 from Laminaria japonica, Rheum palmatum, and Ephedra sinica inhibits visceral obesity and insulin resistance by upregulating visceral adipose genes involved in fatty acid oxidation."